Biological biomarkers
October 2018, Biological Biomarkers in Multiple Sclerosis by Prof Irina Elovaara and Nikolaos C Grigoriadis.
ABSTRACT
Need for biomarkers in MS:
• New therapeutic agents with variable mechanisms of action are available
• The complexity and heterogeneity of MS urges a more differentiated
defining of patients
• Personalized therapy: the information on disease and molecular biomarker profile of a particular patient will contribute to better understanding of their disease, diagnosis and factors that determine response to therapy
IRINA ELOVAARA
MD, PhD Neuroimmunology Unit, University of Tampere &
Department of Neurology, Tampere University Hospital, Finland
NIKOLAOS GRIGORIADIS
MD, PhD Laboratory of Experimental Neurology and Neuroimmunology & Department of Neurology AHEPA University Hospital, Aristotle University of Thessaloniki, Greece